AATec Medical Secures EUR 4 Million to Advance Lead Respiratory Drug Candidate to Clinical Development

Funding from SPRIND and Family Offices accelerates preparation of ATL-105 for clinical development in lead indication non-CF related bronchiectasis by 2026 Munich, Germany – 15.0